Bold claim: A breakthrough in canine stem cell culture uses only dog-derived components, eliminating cross-species concerns altogether. And this is where the story gets even more interesting: a fully canine-made culture system now appears feasible, potentially transforming regenerative medicine for dogs. Here’s how it works, why it matters, and what could come next.
Canine induced pluripotent stem (iPS) cells can become any cell type, making them invaluable for studying common canine diseases and, in some cases, human conditions that share similar biology. To grow these iPS cells, scientists rely on a culture substrate that acts as a scaffold. Cells attach to this scaffold and multiply; without it, they either die or fail to differentiate into the desired lineages.
Traditionally, culture substrates for canine iPS cells have been derived mostly from human proteins. While effective, these human-origin materials are foreign to dog cells. The mismatch can provoke immune reactions and complicate eventual clinical use, especially if the cells are intended for therapy in dogs.
A research team led by graduate student Kohei Shishida and Professor Shingo Hatoya at Osaka Metropolitan University’s Graduate School of Veterinary Science developed a canine-only solution. They engineered Escherichia coli to carry canine genes that drive the production of vitronectin (VTN), a protein native to dogs. The bacteria essentially became tiny factories, producing enough VTN to serve as a scaffold for growing canine iPS cells, all without introducing human- or mouse-derived components.
When tested, the canine-derived VTN performed on par with the human-derived counterpart. The iPS cells maintained their full potential to differentiate, matching results seen in traditional media.
“This achievement is highly significant because it enables the stable cultivation of canine iPS cells without human components,” Shishida commented. “It reduces cross-species contamination risks and supports a fully canine culture system.”
For potential clinical applications, the team also explored a mutant version of VTN, called VTN-N, created by trimming a portion of the protein’s N-terminal region. The aim was to see if removing nonessential parts would affect performance. VTN-N worked as well as the human-derived VTN, functioning effectively with a simpler structure. The researchers plan to optimize manufacturing using VTN-N in future work.
“This research accelerates the clinical potential of regenerative medicine for dogs facing conditions such as heart disease, neurological disorders, and blood disorders,” Hatoya noted. “Canine-derived VTN can be produced in a stable, cost-effective way using E. coli, making it a foundational technology with broad research and clinical applicability.”
The study appears in Regenerative Therapy.
Declaration of Competing Interest
The authors report no conflicts of interest.
About OMU
Osaka Metropolitan University is one of Japan’s largest public universities, committed to advancing society through knowledge convergence and world-class research. For more research news, visit https://www.omu.ac.jp/en/ and follow the university on X, Facebook, Instagram, and LinkedIn.
